Molecular Hydrogen as a Promising Therapy Could Be Linked With Increased Resting Treg Cells or Decreased Fas+ T Cell Subsets in a IgG4-PF-ILD Patient: A Case Report

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Molecular Hydrogen as a Promising Therapy Could Be Linked With Increased Resting Treg Cells or Decreased Fas+ T Cell Subsets in a IgG4-PF-ILD Patient : A Case Report. / Lui, Shan Wen; Lu, Jeng Wei; Ho, Yi Jung; Tang, Shih En; Ko, Kai Hsiung; Hsieh, Ting Yu; Liu, Feng Cheng.

In: In vivo (Athens, Greece), Vol. 38, No. 3, 2024, p. 1512-1518.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Lui, SW, Lu, JW, Ho, YJ, Tang, SE, Ko, KH, Hsieh, TY & Liu, FC 2024, 'Molecular Hydrogen as a Promising Therapy Could Be Linked With Increased Resting Treg Cells or Decreased Fas+ T Cell Subsets in a IgG4-PF-ILD Patient: A Case Report', In vivo (Athens, Greece), vol. 38, no. 3, pp. 1512-1518. https://doi.org/10.21873/invivo.13600

APA

Lui, S. W., Lu, J. W., Ho, Y. J., Tang, S. E., Ko, K. H., Hsieh, T. Y., & Liu, F. C. (2024). Molecular Hydrogen as a Promising Therapy Could Be Linked With Increased Resting Treg Cells or Decreased Fas+ T Cell Subsets in a IgG4-PF-ILD Patient: A Case Report. In vivo (Athens, Greece), 38(3), 1512-1518. https://doi.org/10.21873/invivo.13600

Vancouver

Lui SW, Lu JW, Ho YJ, Tang SE, Ko KH, Hsieh TY et al. Molecular Hydrogen as a Promising Therapy Could Be Linked With Increased Resting Treg Cells or Decreased Fas+ T Cell Subsets in a IgG4-PF-ILD Patient: A Case Report. In vivo (Athens, Greece). 2024;38(3):1512-1518. https://doi.org/10.21873/invivo.13600

Author

Lui, Shan Wen ; Lu, Jeng Wei ; Ho, Yi Jung ; Tang, Shih En ; Ko, Kai Hsiung ; Hsieh, Ting Yu ; Liu, Feng Cheng. / Molecular Hydrogen as a Promising Therapy Could Be Linked With Increased Resting Treg Cells or Decreased Fas+ T Cell Subsets in a IgG4-PF-ILD Patient : A Case Report. In: In vivo (Athens, Greece). 2024 ; Vol. 38, No. 3. pp. 1512-1518.

Bibtex

@article{1baa2645f7ca4575ada1a5bcdbf74ec8,
title = "Molecular Hydrogen as a Promising Therapy Could Be Linked With Increased Resting Treg Cells or Decreased Fas+ T Cell Subsets in a IgG4-PF-ILD Patient: A Case Report",
abstract = "BACKGROUND/AIM: Progressive fibrosing interstitial lung disease (PF-ILD) refers to a group of chronic lung conditions commonly associated with immunoglobulin G4-related disorders. It is characterized by progressive scarring (fibrosis) within the pulmonary interstitium, resulting in respiratory failure and early mortality. Some patients do not respond to standard therapeutic interventions. Numerous studies have confirmed the anti-inflammatory and antioxidant properties of molecular hydrogen in various disease models. CASE REPORT: In this report, we present a case study of an 85-year-old female diagnosed with suspected IgG4-related PF-ILD complicated by hospital-acquired pneumonia. On the fourth day of hydrogen-assisted therapy, a noticeable improvement in lung infiltrations was observed in chest X-rays as the patient gradually progressed towards weaning off mechanical ventilation. To assess treatment responses, we compared immune phenotypes before and after hydrogen treatment. A marked increase was observed in resting regulatory T cell levels after treatment, accompanied by a notable decrease in Fas+ helper T cell and cytotoxic T cell subtypes. CONCLUSION: This case study highlights the effectiveness of hydrogen-assisted therapy in managing PF-ILD complicated by pneumonia, warranting further research in the future.",
keywords = "case report, Fas+ T cell subsets, Hydrogen therapy, progressive fibrosing interstitial lung disease (PF-ILD), resting Treg",
author = "Lui, {Shan Wen} and Lu, {Jeng Wei} and Ho, {Yi Jung} and Tang, {Shih En} and Ko, {Kai Hsiung} and Hsieh, {Ting Yu} and Liu, {Feng Cheng}",
note = "Publisher Copyright: Copyright {\textcopyright} 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.",
year = "2024",
doi = "10.21873/invivo.13600",
language = "English",
volume = "38",
pages = "1512--1518",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "3",

}

RIS

TY - JOUR

T1 - Molecular Hydrogen as a Promising Therapy Could Be Linked With Increased Resting Treg Cells or Decreased Fas+ T Cell Subsets in a IgG4-PF-ILD Patient

T2 - A Case Report

AU - Lui, Shan Wen

AU - Lu, Jeng Wei

AU - Ho, Yi Jung

AU - Tang, Shih En

AU - Ko, Kai Hsiung

AU - Hsieh, Ting Yu

AU - Liu, Feng Cheng

N1 - Publisher Copyright: Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

PY - 2024

Y1 - 2024

N2 - BACKGROUND/AIM: Progressive fibrosing interstitial lung disease (PF-ILD) refers to a group of chronic lung conditions commonly associated with immunoglobulin G4-related disorders. It is characterized by progressive scarring (fibrosis) within the pulmonary interstitium, resulting in respiratory failure and early mortality. Some patients do not respond to standard therapeutic interventions. Numerous studies have confirmed the anti-inflammatory and antioxidant properties of molecular hydrogen in various disease models. CASE REPORT: In this report, we present a case study of an 85-year-old female diagnosed with suspected IgG4-related PF-ILD complicated by hospital-acquired pneumonia. On the fourth day of hydrogen-assisted therapy, a noticeable improvement in lung infiltrations was observed in chest X-rays as the patient gradually progressed towards weaning off mechanical ventilation. To assess treatment responses, we compared immune phenotypes before and after hydrogen treatment. A marked increase was observed in resting regulatory T cell levels after treatment, accompanied by a notable decrease in Fas+ helper T cell and cytotoxic T cell subtypes. CONCLUSION: This case study highlights the effectiveness of hydrogen-assisted therapy in managing PF-ILD complicated by pneumonia, warranting further research in the future.

AB - BACKGROUND/AIM: Progressive fibrosing interstitial lung disease (PF-ILD) refers to a group of chronic lung conditions commonly associated with immunoglobulin G4-related disorders. It is characterized by progressive scarring (fibrosis) within the pulmonary interstitium, resulting in respiratory failure and early mortality. Some patients do not respond to standard therapeutic interventions. Numerous studies have confirmed the anti-inflammatory and antioxidant properties of molecular hydrogen in various disease models. CASE REPORT: In this report, we present a case study of an 85-year-old female diagnosed with suspected IgG4-related PF-ILD complicated by hospital-acquired pneumonia. On the fourth day of hydrogen-assisted therapy, a noticeable improvement in lung infiltrations was observed in chest X-rays as the patient gradually progressed towards weaning off mechanical ventilation. To assess treatment responses, we compared immune phenotypes before and after hydrogen treatment. A marked increase was observed in resting regulatory T cell levels after treatment, accompanied by a notable decrease in Fas+ helper T cell and cytotoxic T cell subtypes. CONCLUSION: This case study highlights the effectiveness of hydrogen-assisted therapy in managing PF-ILD complicated by pneumonia, warranting further research in the future.

KW - case report

KW - Fas+ T cell subsets

KW - Hydrogen therapy

KW - progressive fibrosing interstitial lung disease (PF-ILD)

KW - resting Treg

U2 - 10.21873/invivo.13600

DO - 10.21873/invivo.13600

M3 - Journal article

C2 - 38688598

AN - SCOPUS:85191917934

VL - 38

SP - 1512

EP - 1518

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 3

ER -

ID: 392918152